ALB and neoplasm: In this study, we describe the use of an Flt3L-based immunotherapeutic named albumin-Flt3L (Alb-Flt3L) with potent cross-presenting-DC expansion abilities as an in situ vaccination strategy to promote tumor antigen–specific immunity in combination with standard-of-care chemoradiation.